How are advances in ALL genomics informing new treatment approaches?

During the 63rd ASH Annual Meeting and Exposition, the ALL Hub was pleased to speak with Charles Mullighan, St. Jude Children's Research Hospital, Memphis, US. We asked, How are advances in ALL genomics informing new treatment approaches?


Mullighan begins by highlighting the impact advances in genomics have had on ALL diagnosis and treatment, such as RNA sequencing. He goes into more detail about subtypes and the shortcomings of a gene panel approach for ALL. Mullighan discusses the benefits for patients, such as improved risk stratification, and optimization of novel and conventional therapies. Finally, he highlights the value in tracking clonal mutations and outlines the role of genomics in T-ALL.


See acast.com/privacy for privacy and opt-out information.